Global Type 2 Diabetes Market is expected to grow at CAGR 6.7% by 2028 due to introduction of novel approaches by researchers, says Absolute Markets Insights

The protein named adipsin, which is produced in body fat enables to protect insulin-secreting cells called pancreatic beta cells from destruction in type 2 diabetes. This is in accordance to a new study published by researchers at Weill Cornell Medicine and NewYork-Presbyterian. Higher levels of the protein in the blood were also associated with protection from type 2 diabetes amongst the middle-aged adults. A challenge associated with type 2 diabetes is that beta cells stop functioning properly and fade away. About 31.09 million people in the United States have diabetes, and up to 95.01% of these individuals have the type 2 form of the disease, in which the body stops responding to insulin and pancreatic beta cells slowly stop producing enough of it. Side effects associated with medications that target beta cells include lowering blood glucose levels at significant level. There are no proven treatments to prevent beta cell loss. Patients suffering from type 2 diabetes whose beta cells doesn’t work properly have to inject insulin to keep their blood glucose levels at a uniform level. In such a situation, researchers such as Drs. Mingming Hao, Noah Dephoure and Dr. Lukas Dow at Weill Cornell Medicine knew the potential of adipsin to control the stimulating beta cells to secrete insulin and theorized that the protein might be a potential therapy for type 2 diabetes treatment.

Request for Sample Copy of This Report@

To prove this theory right, the scientists first conducted a study in which they increased adipsin levels in mice with type 2 diabetes. It was found that adipsin had a long-term positive effect on diabetes, improving blood sugar and increasing insulin levels while helping to prevent beta cell death, thus assisting the growth of the global type 2 diabetes market. Dr. Lo and his fellow collaborators at Icahn School of Medicine at Mount Sinai also studied about the human beta cells in their laboratories and determined that adipsin activates a molecule called C3a, which protects and supports beta cell function, thus preventing the loss of beta cells at a larger amount. They further discovered that C3a suppresses an enzyme called Dusp26 that can damage beta cells and cause them to die. The researchers then directly blocked DUSP26 activity in human beta cells and found that this treatment protected the beta cells from death. Similarly, when they suppressed DUSP26 activity in mice, beta cells became healthier, meaning they could secrete insulin in a better manner. Thus, both adipsin and DUSP26-directed therapies may prevent type 2 diabetes patients from developing beta cell failure and from requiring insulin injections for their treatment. The study was duly published on November 8, 2019. To gain an adept understanding of how adipsin might be influencing the health of people in the community, the team collaborated with researchers at Harvard Medical School and Massachusetts General Hospital to evaluate 5570 individuals enrolled in Framingham Heart Study, an ongoing cardiovascular study conducted in Massachusetts. Such a factor has aided the growth of Type 2 Diabetes market in the recent past and is expected to continue the same trend over the next eight years (2020 to 2028).

Some of the players operating in the type 2 diabetes market include Abbott Laboratories Inc., Acon Laboratories Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma and Takeda Pharmaceuticals amongst others.

Enquiry Before Buying @

The detailed research study provides qualitative and quantitative analysis of the global type 2 diabetes market. The type 2 diabetes market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America

Request for Customization@

Global Type 2 Diabetes Market :


  • By Treatment+Devices
    • Treatment
      • Drug
      • Alpha-Glucosidase Inhibitors
      • Others
    • Devices
      • Blood Glucose Monitoring
      • Insulin Delivery Devices
    • By Region:
    • North America
      • S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America


Get Full Information of this premium report@

About Us:

Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …

Contact Us:

Email id:

Contact Name: Shreyas Tanna

Phone: +91-740-024-2424


Back to top button